Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate
Status:
Completed
Trial end date:
2018-08-15
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, randomized, double blind, double dummy, placebo and
active-controlled, parallel group study to assess the efficacy and safety of PF 06650833 at
Week 12 in subjects with moderate-severe, active, RA who have had an inadequate response to
MTX. PF-06650833 or matching placebo tablets will be administered orally QD under fasting
conditions, and tofacitinib or matching tofacitinib placebo tablets will be administered
orally BID for 12 weeks in a blinded fashion.